Related Experiment Video
Updated: Sep 21, 2025

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
Bacteriophage-antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa: In vitro synergy testing
Dana J Holger1, Katherine L Lev1, Razieh Kebriaei1
1Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Aims:
Here, we investigate the impact of phage-antibiotic combinations (PAC) on bacterial killing, resistance development and outer membrane vesicle (OMV) production in multidrug-resistant (MDR) P. aeruginosa.
Methods And Results:
After screening 10 well-characterized MDR P. aeruginosa strains against three P. aeruginosa phages, representative strains, R10266 and R9316, were selected for synergy testing based on high phage sensitivity and substantial antibiotic resistance patterns, while phage EM was chosen based on host range. To understand the impact of phage-antibiotic combinations (PAC) against MDR P. aeruginosa, time-kill analyses, OMV quantification and phage/antibiotic resistance testing were performed. Phage and meropenem demonstrated synergistic activity against both MDR strains. Triple combination regimens, phage-meropenem-colistin and phage-ciprofloxacin-colistin, resulted in the greatest CFU reduction for strains R9316 (3.50 log10 CFU ml-1 ) and R10266 (4.50 log10 CFU ml-1 ) respectively. PAC resulted in regained and improved antibiotic susceptibility to ciprofloxacin (MIC 2 to 0.0625) and meropenem (MIC 32 to 16), respectively, in R9316. Phage resistance was prevented or reduced in the presence of several classes of antibiotics and OMV production was reduced in the presence of phage for both strains, which was associated with significantly improved bacterial eradication.
Conclusions:
These findings support the potential of phage-antibiotic synergy (PAS) to augment killing of MDR P. aeruginosa. Systematic in vitro and in vivo studies are needed to better understand phage interactions with antipseudomonal antibiotics, to define the role of OMV production in P. aeruginosa PAC therapy and to outline pharmacokinetic and pharmacodynamic parameters conducive to PAS.
Significance And Impact Of Study:
This study identifies novel bactericidal phage-antibiotic combinations capable of thwarting resistance development in MDR and XDR P. aeruginosa strains. Furthermore, phage-mediated OMV reduction is identified as a potential mechanism through which PAC potentiates bacterial killing.
Insights
Phage-antibiotic combinations (PAC) show promise in treating multidrug-resistant Pseudomonas aeruginosa by enhancing bacterial killing and preventing resistance. Phage-mediated outer membrane vesicle reduction is a key mechanism in this synergistic effect.
Area of Science:
- Microbiology
- Bacteriology
- Antimicrobial Resistance
Background:
- Multidrug-resistant (MDR) Pseudomonas aeruginosa poses a significant threat due to limited treatment options.
- Bacteriophages and antibiotics are explored as monotherapies, but their synergistic potential is under investigation.
Purpose of the Study:
- To investigate the impact of phage-antibiotic combinations (PAC) on bacterial killing, resistance development, and outer membrane vesicle (OMV) production in MDR P. aeruginosa.
- To identify effective PAC regimens and understand their mechanisms of action.
Main Methods:
- Screening of MDR P. aeruginosa strains against phages and antibiotics.
- Time-kill analyses, OMV quantification, and phage/antibiotic resistance testing were performed.
- Synergy testing of phage-meropenem and phage-ciprofloxacin-colistin combinations.
Main Results:
- Phage and meropenem demonstrated synergistic activity against MDR P. aeruginosa.
- Triple combination regimens achieved significant bacterial CFU reduction.
- PAC restored antibiotic susceptibility and prevented phage resistance.
- Phage-mediated OMV reduction was associated with improved bacterial eradication.
Conclusions:
- Phage-antibiotic synergy (PAS) shows potential for augmenting the killing of MDR P. aeruginosa.
- Novel bactericidal PACs were identified that thwart resistance development in MDR and extensively drug-resistant (XDR) P. aeruginosa.
- Phage-mediated OMV reduction is a potential mechanism potentiating bacterial killing in PAC therapy.
Related Concept Videos
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Lytic Cycle of Bacteriophages
Gene Regulation in Microbial Communities: Quorum Sensing
Antibiotic Selection

